Osteoclasts in Multiple Myeloma Are Derived from Gr-1+CD11b+Myeloid-Derived Suppressor Cells

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Zhuang, Junling ^a,b   Zhang, Jianghong ^a   Lwin, Seint T ^a   Edwards, James R ^a   Edwards, Claire M ^a   Mundy, Gregory R ^a   Yang, Xiangli ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD11B ANTIGEN; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BONE DESTRUCTION; BONE LESION; BONE MARROW; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOUSE; MULTIPLE MYELOMA; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRENYLATION; SPLEEN; SUPPRESSOR CELL; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD11B; BONE AND BONES; CELL DIFFERENTIATION; CELL LINE, TUMOR; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MICE; MULTIPLE MYELOMA; MYELOID CELLS; OSTEOCLASTS; PRENYLATION; TUMOR MICROENVIRONMENT;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84869222349     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048871     Document Type: Article

References (38)

1. Kaplan RN, Rafii S, Lyden D, (2006) Preparing the "soil": the premetastatic niche. Cancer research 66: 11089-11093.
2. Kaplan RN, Psaila B, Lyden D, (2007) Niche-to-niche migration of bone-marrow-derived cells. Trends in molecular medicine 13: 72-81.
3. Kaplan RN, Psaila B, Lyden D, (2006) Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer metastasis reviews 25: 521-529.
4. Psaila B, Kaplan RN, Port ER, Lyden D, (2006) Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. Breast disease 26: 65-74.
5. Edwards CM, Zhuang J, Mundy GR, (2008) The pathogenesis of the bone disease of multiple myeloma. Bone 42: 1007-1013.
6. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, et al. (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+T cells. The Journal of clinical investigation 116: 2777-2790.
7. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, et al. (2004) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer research 64: 6337-6343.
8. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, et al. (2004) Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
9. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S, (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. Journal of immunology 179: 977-983.
10. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, et al. (2008) Tumor-induced CD11b+Gr-1+myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. Journal of immunology 181: 3291-3300.
11. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S, (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer research 70: 68-77.
12. Bataille R, Harousseau JL, (1997) Multiple myeloma. The New England Journal of Medicine 336: 1657-1664.
13. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC, (2009) Multiple myeloma. Lancet 374: 324-339.
14. Guise TA, Chirgwin JM (2003) Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clinical orthopaedics and related research: S32-38.
15. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, et al. (2005) Molecular mechanisms of breast cancer metastases to bone. Clinical breast cancer 5Suppl: S46-53.
16. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, et al. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484-2491.
17. Chambers TJ, (2010) The birth of the osteoclast. Annals of the New York Academy of Sciences 1192: 19-26.
18. Massey HM, Flanagan AM, (1999) Human osteoclasts derive from CD14-positive monocytes. British journal of haematology 106: 167-170.
19. Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, et al. (1999) Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 93: 1697-1706.
20. Radl J, (1999) Multiple myeloma and related disorders. Lessons from an animal model. Pathologie-biologie 47: 109-114.
21. Fowler JA, Mundy GR, Lwin ST, Lynch CC, Edwards CM, (2009) A murine model of myeloma that allows genetic manipulation of the host microenvironment. Disease models & mechanisms 2: 604-611.
22. Avcu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, et al. (2005) The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. European journal of haematology 74: 496-500.
23. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, et al. (2008) Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111: 2833-2842.
24. Hofmann G, Bernabei PA, Crociani O, Cherubini A, Guasti L, et al. (2001) HERG K+channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1. The Journal of biological chemistry 276: 4923-4931.
25. Granholm S, Lundberg P, Lerner UH, (2008) Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation. Journal of cellular biochemistry 104: 920-933.
26. Derenne S, Amiot M, Barille S, Collette M, Robillard N, et al. (1999) Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 14: 2048-2056.
27. Roelofs AJ, Hulley PA, Meijer A, Ebetino FH, Russell RG, et al. (2006) Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. International journal of cancer Journal international du cancer 119: 1254-1261.
28. Green JR, Muller K, Jaeggi KA, (1994) Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 9: 745-751.
29. Porfiri E, Evans T, Chardin P, Hancock JF, (1994) Prenylation of Ras proteins is required for efficient hSOS1-promoted guanine nucleotide exchange. The Journal of biological chemistry 269: 22672-22677.
30. Zhang FL, Casey PJ, (1996) Protein prenylation: molecular mechanisms and functional consequences. Annual review of biochemistry 65: 241-269.
31. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ, (1999) Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Molecular pharmacology 56: 131-140.
32. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. (1999) Molecular mechanisms of action of bisphosphonates. Bone 24: 73S-79S.
33. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, et al. (2007) MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. The Journal of experimental medicine 204: 1463-1474.
34. Liu Q, Zhang M, Jiang X, Zhang Z, Dai L, et al. (2011) miR-223 suppresses differentiation of tumor-induced CD11b Gr1 myeloid-derived suppressor cells from bone marrow cells. International journal of cancer Journal international du cancer 129: 2662-2673.
35. Kim YS, Kim YJ, Lee JM, Kim EK, Park YJ, et al. (2012) Functional Changes in Myeloid-Derived Suppressor Cells (MDSCs) during Tumor Growth: FKBP51 Contributes to the Regulation of the Immunosuppressive Function of MDSCs. Journal of immunology 188: 4226-4234.
36. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, et al. (2009) Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PloS one 4: e6896.
37. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine 341: 1565-1571.
38. van Rhee F, Dhodapkar M, Shaughnessy JD Jr, Anaissie E, Siegel D, et al. (2008) First thalidomide clinical trial in multiple myeloma: a decade. Blood 112: 1035-1038.